Cell-Based Potency Assays

Cell-based potency assays are bioassays that quantitatively measure a drug’s biological activity in living cells, designed to reflect the product’s mechanism of action (MOA).

• Legacy: Animal-based assays These methods are slow, have very high variability, are expensive, and pose ethical challenges.
• Established Standard: In vitro cell-based assays using well-characterized, immortalized cell lines. The biological response is typically measured using a plate reader.
• Emerging Alternatives: More physiologically relevant systems like 3D cell cultures, organoids, or primary cells. Analysis is also advancing through high-content imaging and flow cytometry, which allow for the measurement of multiple functional parameters simultaneously.

Cell-based potency assays measure a dose-dependent biological response. The core principle involves comparing the dose-response curve of a test sample to that of a qualified in-house Reference Standard.

1. Preparation: A specific, responsive cell line is cultured and plated in a multi-well format.
2. Dose Application: The test sample and the Reference Standard are serially diluted to create a range of concentrations and are added to the cells.
3. Incubation: The cells are incubated for a defined period to allow the product to elicit its biological effect (e.g., induce protein expression, inhibit cell growth).
4. Readout: A reagent is added to generate a measurable signal (e.g., light, fluorescence) that is proportional to the biological response. The signal is read by an instrument like a plate readerfireworks .
5. Calculation: The dose-response curves of the sample and reference standard are compared using statistical analysis (e.g., parallel line analysis) to determine the Relative Potency of the sample.

• Output: A set of dose-response curves (typically sigmoidal) for the test sample and the reference standard on the same plate.
• Analysis: Statistical software is used to fit the curves to a parallel-line or four-parameter logistic (4-PL) model. The key outputs are the calculated Relative Potency (often reported as a percentage of the reference standard) and a measure of parallelism between the curves.
• Interpretation: For a test to be valid, the curves must be parallel, and the quality controls must meet their criteria. The calculated Relative Potency of the batch must fall within the approved specification range (e.g., 80-125%).

• MOA-Reflective: Directly measures the product's intended biological function, providing a strong link to clinical efficacy.
• High Biological Relevance: Sensitive to structural changes (like glycosylation or aggregation) that can impact function but may be missed by physicochemical tests.
• Comprehensive: An integrative measure of overall product quality, as many attributes can collectively impact the final potency result.

• High Variability: Cell-based bioassays are inherently more variable than standard physicochemical assays due to the complexity of the biological system.
• Low Throughput: These assays are often slow, with multi-day incubations and complex, manual cell culture steps.
• Reference Standard Dependent: The result is relative to the in-house reference standard. The consistency and characterization of this standard are paramount.
• Assay-to-Clinic Correlation: Demonstrating that an in vitro assay result is truly representative of the in vivo clinical effect can be a significant challenge.

• Phase-Appropriate Approach: Validation expectations increase with clinical development. Early-phase assays are "fit-for-purpose," while late-stage/commercial assays must be fully validated.
• Parallelism: A critical system suitability criterion. The dose-response curves for the sample and standard must be parallel to ensure the assay is measuring the same biological activity. This is the most critical statistical test, mathematically demonstrating that the test sample and reference standard behave in a similar biological manner. A lack of parallelism invalidates the result and can indicate that the test sample has a different mechanism of action or contains impurities that interfere with the expected biological response
• Precision: Intermediate precision is often the most challenging validation parameter to achieve due to the inherent variability of cell-based methods.
• Accuracy: Assessed by measuring samples with a known relative potency against the reference standard.

Standardization of cell-based potency assays is essential to ensure comparability across batches, sites, and time. Results are inherently relative, so a well-characterized in-house reference standard—anchored to clinical lots and supported by stability data—is required for calculating potency. Industry best practice includes lifecycle management of this reference, bridging studies when new lots are introduced, and system suitability controls (e.g., parallelism checks). Global discussions are ongoing to develop common reference materials and assay frameworks to reduce variability across laboratories and support regulatory alignment.

• AAV Gene Therapy: The potency assay is typically a transduction assay. Target cells are infected with the AAV vector, and the functional consequence of the transgene is measured (e.g., expression of the target protein via ELISA, or mRNA expression via qPCR). Potency is functionally linked to the Vector Genome Titer and Empty/Full Ratio.
• Monoclonal Antibodies (mAbs): The assay is designed to measure the specific MOA. Common examples include target binding assays (ELISA), cell-killing assays (for oncology mAbs), or neutralization assays (for anti-viral mAbs).
• mRNA-LNP Products: A transfection assay is used. Target cells are treated with the mRNA-LNP, and the expression of the encoded protein is measured via a method like flow cytometry or ELISA.